Latest news with #Behcet'sDisease
Globe and Mail
09-04-2025
- Health
- Globe and Mail
Behcet's Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports
The Key Behcet's Disease Companies in the market include - Soligenix, Chugai Pharmaceutical, UMC Utrecht, Ganzhou Hemay Pharmaceutical, Amgen, and others. DelveInsight's 'Behcet's Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Behcet's Disease, historical and forecasted epidemiology as well as the Behcet's Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Behcet's Disease Market Report: The Behcet's Disease market size was value ~USD 140 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In March 2025, Christopher J. Schaber, PhD, President and CEO of Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with significant unmet needs, stated that the company remains committed to advancing its diverse clinical pipeline. Key upcoming milestones include the anticipated top-line results in 2026 from the ongoing confirmatory Phase 3 placebo-controlled trial evaluating HyBryte™ (synthetic hypericin) for early-stage cutaneous T-cell lymphoma (CTCL). Additionally, in the latter half of this year, Soligenix expects to announce top-line data from its ongoing Phase 2 trials of SGX945 (dusquetide) for Behçet's disease and SGX302 (synthetic hypericin) for mild-to-moderate psoriasis. In November 2024, Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with unmet medical needs, announced the initiation of patient enrollment for its Phase 2 clinical trial (protocol number DUS-AUBD-01) assessing SGX945 (dusquetide) as a treatment for Behçet's Disease. Among the EU4 and the UK, Italy has the largest market size at around USD 10 million, followed by France with approximately USD 8 million. These figures are anticipated to change over the forecast period (2024-2034) due to ongoing research and development efforts, which may result in the discovery of more effective treatments for Behcet's Syndrome. In January 2024, Soligenix announced that the US Food and Drug Administration (FDA) has granted fast track designation to SGX945 (dusquetide) In 2023, Japan had the highest number of diagnosed prevalent cases of Behcet's syndrome among the 7MM countries. In 2023, Italy had the highest number of diagnosed prevalent cases among the EU4 and the UK, with approximately 7,000 cases. This number is expected to increase by 2034. In 2023, the total diagnosed prevalent cases of Behcet's Syndrome in the US were approximately 3,500 for pediatric patients and around 16,000 for young adults. Among the clinical manifestations of Behcet's Syndrome in the US, oral ulcers were the most prevalent, representing about 30% of the total cases, followed by genital ulcers. In the EU4 countries and the UK, oral ulcers were the most common, with approximately 5,000 cases, followed by genital ulcers, which accounted for around 3,000 cases. Key Behcet's Disease Companies: Soligenix, Chugai Pharmaceutical, UMC Utrecht, Ganzhou Hemay Pharmaceutical, Amgen, and others Key Behcet's Disease Therapies: SGX945, RAY121, Dusquetide, Filgotinib, Hemay005, Apremilast, and others The Behcet's Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Behcet's Disease pipeline products will significantly revolutionize the Behcet's Disease market dynamics. Behcet's Disease Overview Behcet's Disease is a rare, chronic, and multisystem inflammatory disorder characterized by recurring episodes of inflammation affecting various parts of the body. It is named after the Turkish dermatologist Hulusi Behçet, who first described the condition in 1937. The disease primarily affects blood vessels, causing symptoms that can involve the mouth, eyes, skin, joints, and other organs. Behcet's Disease Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Behcet's Disease Epidemiology Segmentation: The Behcet's Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases of Behcet's Syndrome in the 7MM Diagnosed Cases of Behcet's Syndrome Based on the Age of Onset in the 7MM Clinical Manifestations Associated With Behcet's Syndrome in the 7MM Total Patients Seeking Treatment for Behcet's Syndrome in the 7MM Download the report to understand which factors are driving Behcet's Disease epidemiology trends @ Behcet's Disease Epidemiology Forecast Behcet's Disease Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Behcet's Disease market or expected to get launched during the study period. The analysis covers Behcet's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Behcet's Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Behcet's Disease Therapies and Key Companies SGX945: Soligenix RAY121: Chugai Pharmaceutical Dusquetide: Soligenix Filgotinib: UMC Utrecht Hemay005: Ganzhou Hemay Pharmaceutical Apremilast: Amgen Discover more about therapies set to grab major Behcet's Disease market share @ Behcet's Disease Treatment Landscape Behcet's Disease Market Strengths The constant efforts by researchers to determine clear molecular pathogenesis are progressively increasing. Studies suggest that Behcet's syndrome shares common features with autoimmune and inflammatory disorders, thus leading to the detection of the main mediators involved in the pathomechanism of Behcet's syndrome. Behcet's Disease Market Opportunities There is an attractive market for therapies with a primary goal of treatment to rapidly suppress and prevent new inflammatory attacks to avoid irreversible organ damage, especially in the early, active stages of Behcet's syndrome. As a consequence of escalating knowledge and awareness among providers and caregivers about Behcet's syndrome, the prevalence of the disease is increasing, which may further expedite the R&D. Scope of the Behcet's Disease Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Behcet's Disease Companies: Soligenix, Chugai Pharmaceutical, UMC Utrecht, Ganzhou Hemay Pharmaceutical, Amgen, and others Key Behcet's Disease Therapies: SGX945, RAY121, Dusquetide, Filgotinib, Hemay005, Apremilast, and others Behcet's Disease Therapeutic Assessment: Behcet's Disease current marketed and Behcet's Disease emerging therapies Behcet's Disease Market Dynamic s: Behcet's Disease market drivers and Behcet's Disease market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Behcet's Disease Unmet Needs, KOL's views, Analyst's views, Behcet's Disease Market Access and Reimbursement Table of Contents 1. Behcet's Disease Market Report Introduction 2. Executive Summary for Behcet's Disease 3. SWOT analysis of Behcet's Disease 4. Behcet's Disease Patient Share (%) Overview at a Glance 5. Behcet's Disease Market Overview at a Glance 6. Behcet's Disease Disease Background and Overview 7. Behcet's Disease Epidemiology and Patient Population 8. Country-Specific Patient Population of Behcet's Disease 9. Behcet's Disease Current Treatment and Medical Practices 10. Behcet's Disease Unmet Needs 11. Behcet's Disease Emerging Therapies 12. Behcet's Disease Market Outlook 13. Country-Wise Behcet's Disease Market Analysis (2020–2034) 14. Behcet's Disease Market Access and Reimbursement of Therapies 15. Behcet's Disease Market Drivers 16. Behcet's Disease Market Barriers 17. Behcet's Disease Appendix 18. Behcet's Disease Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Associated Press
21-02-2025
- Health
- Associated Press
Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's Disease
DETROIT, MICHIGAN - February 21, 2025 ( NEWMEDIAWIRE) - The human body's circulatory system is comprised of blood vessels that carry blood away from and towards the heart. A specific distinction is that arteries carry blood away from the heart, veins carry blood back to the heart and capillaries are tiny blood vessels that connect arteries and veins, allowing for the exchange of oxygen, nutrients and waste products between the blood and body tissues. The human circulatory system is made up of about 60,000 miles of blood vessels, including arteries, veins and capillaries – this is long enough to stretch around the Earth if laid end-to-end. Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases and areas of unmet medical need, is utilizing its pharmaceutical expertise to treat Behcet's disease, an autoimmune condition mainly associated with inflammation of the blood vessels and the eyes, though the inflammation of the blood vessels often causes many different issues throughout the body. Behcet's Disease Explained Behcet's disease, or Silk Road disease, is a non-curable long-term condition caused by blood vessel inflammation. This inflammation affects and damages both the arteries and veins. Primarily diagnosed in young adults, its effects and severity will vary over time. Indications of the disease within individuals usually include mouth sores, skin rashes and lesions, genital sores, leg ulcers and eye inflammation, with inflammation of the joints observed in the most severe cases. It is a painful disease that directly impacts the patient's quality of life and ability to engage in life activities, including working productively. Demographically, as its alternate name suggests, the disease is most common along the 'Silk Road' in the Middle East and East Asia, including Turkey, Iran, Japan and China. It is less prevalent in the U.S. but can develop at any age, equally affecting both men and women. Behcet's Disease Addressable Market According to estimates compiled by Soligenix, as many as 1,000,000 people worldwide live with Behcet's Disease, with approximately 18,000 known cases in the U.S. and 80,000 in Europe. As reported by BioSpace, the market for Behcet's disease is estimated to reach $184.5 million by 2035; it is currently valued at $105.1 million (2024). The market growth is attributed to the adoption of advanced, minimally invasive treatment options such as biologic therapies, monoclonal antibodies and targeted immunomodulators. These treatments effectively address underlying inflammation and systemic symptoms while reducing side effects and long-term reliance on corticosteroids, such as prednisone. Current therapies suppress inflammation and immune function. Soligenix's Treatment Of Behcet's Disease Soligenix's drug candidate for treating Behcet's disease is SGX945. Dusquetide, the active ingredient in SGX945, is an innate defense regulator (IDR), a new class of short, synthetic peptides. It has a novel mechanism of action whereby it modulates the body's reaction to both injury and infection towards an anti-inflammatory, anti-infective and tissue healing response. IDRs have no direct antibiotic activity, but by modulating the host's innate immune system responses, they can increase survival after infections caused by a broad range of bacterial Gram-negative and Gram-positive pathogens. Dusquetide also accelerates the resolution of tissue damage following exposure to a variety of agents, including bacterial pathogens, trauma and chemo- and/or radiation therapy. SGX945's treatment is administered as a 4-minute IV infusion twice a week. It is intended for use to enhance the resolution of oral, genital and skin ulcer flares in Behçet's Disease. In 2024, Soligenix announced the phase 2 clinical trial of SGX945 in treating Behcet's Disease. The clinical trial will be an open-label study that will enroll approximately 25 patients aged 18 years or older with mild to moderate Behcet's Disease and active oral and/or genital ulcers. Patients will receive SGX945 as a twice weekly 4-minute intravenous (IV) infusion for 4 weeks, followed by 4 weeks of follow-up. Efficacy endpoints will include the extent of lesion clearance, timeline to lesion clearance and patient-reported quality of life assessments. Regarding the launch of the clinical study, Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix, stated, 'We are pleased to have received FDA clearance and Turkish Medicines and Medical Devices Agency (Turkey's Ministry of Health) authorization to start patient enrollment into our SGX945 Phase 2a pilot trial in aphthous ulcers of Behcet's Disease. Our previous studies with dusquetide in oral mucositis have validated the biologic activity in aphthous ulcers induced by chemotherapy and radiation. Given the role of the innate immune system in ulcers associated with Behcet's Disease, and the unmet medical need particularly for more severe ulcers such as genital and leg ulcers, we believe that dusquetide may offer significant relief to patients. We are excited to expand dusquetide's development into different innate immune-related inflammatory conditions, such as Behcet's Disease, as a component of our long-term strategy to enhance the value of this unique compound.' Looking Ahead The launch of the phase 2 clinical trial of SGX945 is a milestone moment for Soligenix. As the firm progresses in treating Behcet's Disease and other rare diseases, it is looking to establish a distinct value proposition in the market that cannot be easily replicated or counter-positioned against. As the firm continues on its product development initiatives, new opportunities for sustainable growth may emerge over time, potentially strengthening its market position. Featured photo by Lucas Vasques on Unsplash.
